Mindray (300760) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
30 Oct, 2025Executive summary
Q3 revenue reached ¥9.09 billion, up 1.53% year-over-year, marking a turnaround after previous declines.
Net profit attributable to shareholders for Q3 was ¥2.50 billion, down 18.69% year-over-year; YTD net profit fell 28.83%.
International business in Q3 grew 11.93% year-over-year, with Europe exceeding 20% growth and strong double-digit gains in CIS and Middle East/Africa.
R&D investment for the first three quarters was ¥2.69 billion, 10.4% of revenue, with continued product innovation and patent growth.
Financial highlights
YTD revenue was ¥25.83 billion, down 12.38% year-over-year.
YTD net profit attributable to shareholders was ¥7.57 billion, down 28.83% year-over-year.
Operating cash flow for Q3 was ¥7.27 billion, down 34.32% year-over-year, mainly due to reduced cash from sales and services.
Basic EPS for Q3 was ¥2.0641, down 18.62% year-over-year; YTD basic EPS was ¥6.2481, down 28.84%.
Total assets at Q3-end were ¥59.27 billion, up 4.63% from year-end; equity attributable to shareholders was ¥39.30 billion, up 9.60%.
Outlook and guidance
Q4 revenue growth is expected to accelerate compared to Q3, with international business momentum and ongoing global supply chain and localization efforts.
Latest events from Mindray
- H1 2025 revenue and profit declined sharply, but international growth and digital transformation continue.300760
H1 202528 Aug 2025 - Double-digit profit and revenue growth, strong IVD, cardiovascular entry, high dividend.300760
H1 202423 Jul 2025 - Revenue and profit rose 8% year-over-year, led by strong international growth.300760
Q3 202423 Jul 2025 - AI-powered, multi-disciplinary solutions drive efficiency and global expansion in healthcare.300760
43rd Annual J.P. Morgan Healthcare Conference Presentation23 Jul 2025 - International growth and strong dividends offset domestic softness; recovery expected.300760
Q1 202523 Jul 2025 - 2024FY saw modest growth and robust international expansion, with recovery expected in late 2025.300760
H2 202423 Jul 2025